2183.T Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 09:15):

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide...

Stats
Šios dienos apimtis	31 300.00
Vidutinė apimtis	106 164
Rinkos kapitalizacija	9.24B
EPS	¥0 ( 2024-02-13 )
Kita pelno data	( ¥0 ) 2024-05-12
Last Dividend	¥14.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	13.57
ATR14	¥1.087 (0.27%)

Linical Co., Ltd. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Linical Co., Ltd. Finansinės ataskaitos

Annual	2022
Pajamos:	¥12.52B
Bruto pelnas:	¥4.16B (33.25 %)
EPS:	¥44.47

FY	2022
Pajamos:	¥12.52B
Bruto pelnas:	¥4.16B (33.25 %)
EPS:	¥44.47

FY	2022
Pajamos:	¥11.56B
Bruto pelnas:	¥3.61B (31.26 %)
EPS:	¥35.00

FY	2021
Pajamos:	¥10.28B
Bruto pelnas:	¥2.77B (26.92 %)
EPS:	¥23.91

Financial Reports:

No articles found.

Linical Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥0 (N/A)	¥14.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Linical Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.80 - Stable (3.94%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥3.00	2009-03-26
Last Dividend	¥14.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	¥111.75	--
Avg. Dividend % Per Year	0.00%	--
Score	3.04	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.80
Div. Directional Score	7.92	--

Next Divdend (Est)
(2024-12-31)

¥0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

3.04

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
7962.T	Ex Dividend Knight	2023-12-19	Semi-Annually	0.00%
7191.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6440.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
5440.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4437.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
3627.T	Ex Dividend Junior	2024-02-28	Annually	0.00%
2820.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
1515.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9744.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8801.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0543	1.500	8.91	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0385	1.200	8.72	10.00	[0 - 0.3]
returnOnEquityTTM	0.0876	1.500	-0.138	-0.206	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.712	0.800	6.44	5.15	[1 - 3]
quickRatioTTM	1.467	0.800	6.08	4.86	[0.8 - 2.5]
cashRatioTTM	1.018	1.500	5.46	8.19	[0.2 - 2]
debtRatioTTM	0.154	-1.500	7.43	-10.00	[0 - 0.6]
interestCoverageTTM	71.54	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.349	-1.500	8.60	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.324	1.000	7.93	7.93	[0.2 - 0.8]
operatingProfitMarginTTM	0.0925	1.000	-0.151	-0.151	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.372	1.000	9.05	9.05	[0.2 - 2]
assetTurnoverTTM	0.708	0.800	8.61	6.89	[0.5 - 2]
Total Score				11.04

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.61	1.000	8.73	0	[1 - 100]
returnOnEquityTTM	0.0876	2.50	-0.0884	-0.206	[0.1 - 1.5]
freeCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	3.66	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.503	1.500	9.98	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0810	1.000	-0.474	0	[0.1 - 0.5]
Total Score				4.80

Linical Co., Ltd.

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.